AGPS and kidney disorder: Of the 2 patients who were ADA-positive at baseline (binding and neutralizing ADAs), 1 patient experienced no change in kidney disease status (eGFR slope − 4.55 pre-switch to − 3.29 mL/min/1.73 m2/year post-switch), and 1 experienced a positive change from fast-progressing to stable kidney disease (eGFR slope − 7.49 pre-switch to + 3.59 mL/min/1.73 m2/year post-switch).